Sarepta Therapeutics shares are halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.
Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients
